Exfoliating Acids and Barrier Care Patents: Leaders & Trends 2026
- 26.1% concentration at the top. The five leading assignees account for 641 of the 2,457 records in scope, with a long tail of single- and low-filing entrants behind them.
- Filing has cooled from its 2022 peak. Volume ran from 60 in 2017 to a peak of 228 in 2022, and the 2021-to-2024 span shows a 17% pullback — though 2025-26 counts are still filling in due to publication lag.
- A61K dominates, but the field spans further. 71.6% of records carry an A61K medicinal-preparations class, while smaller but sizeable shares sit in A61Q cosmetics use, C07D heterocyclics and A01N biocides.
Filing growth compares 2021 (152 records) with 2024 (126) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 2,457 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Exfoliating acid and barrier care patents sit at the intersection of topical pharmaceutical formulation and cosmetic actives. The search scope combines alpha hydroxy acid, chemical exfoliation and skin barrier care concepts with formulation-control terms such as free acid value, buffering, irritation threshold and label warning — the practical levers formulators pull to keep an active exfoliant tolerable at use concentration.
The 2,457 records in scope run from 2015 through the middle of 2026, spanning original pharmaceutical filings on topical delivery vehicles as well as more recent cosmetics-use and cosmetic-formulation filings. Because a single record can carry classifications spanning medicinal preparations, therapeutic activity, cosmetics use and heterocyclic chemistry, the technology composition below is read as overlapping shares of the same record set, not as mutually exclusive buckets.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Trend, technology mix and jurisdictions
The figures below are drawn directly from the dataset in scope: a filing-year trend, an IPC subclass breakdown, and the receiving offices where applicants have chosen to seek protection.
Filing trend, 2017-2026
Filings rose from 60 in 2017 to a peak of 228 in 2022, then eased; the 2021-to-2024 window shows a 17% decline (152 to 126). 2025 and 2026 counts are understated because publication typically lags filing by around 18 months.
Technology composition by IPC subclass
A61K medicinal preparations covers 71.6% of the 2,457 records, well ahead of A61P therapeutic activity (31.5%), A61Q cosmetics use (29.2%) and C07D heterocyclic compounds (27.5%). Smaller shares in A01N, C07K, C12N and C01B point to biocide, peptide, microbial and inorganic-chemistry adjacencies that touch the same formulations.
Shares are the percentage of the 2,457 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Exfoliating Acids and Barrier Care with Eureka
This page is one run against one query. Ask Eureka your own question about exfoliating acids and barrier care and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited prior art
US20060269495A1 — Alpha hydroxy acid compositions (Stiefel Laboratories)
Pharmaceutical compositions suitable for topical administration comprising an alpha hydroxy acid. In a particular aspect, these compositions exhibit improved tolerance on the skin upon topical application despite the presence of high levels of alpha hydroxy acids in the composition. These compositions are used for topical medical applications, particularly to treat various skin disorders.Filed as a pharmaceutical composition rather than a cosmetic one — a distinction that matters for anyone drafting around tolerance claims at high AHA loading.
View full filing| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20060110415A1 | Topical Delivery System for Cosmetic and Pharmaceutical Agents | 557 |
| 2 | US20080069779A1 | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof | 395 |
| 3 | US20020064541A1 | Composition exhibiting enhanced formulation stability and delivery of topical active ingredients | 316 |
| 4 | US20080206155A1 | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses | 298 |
| 5 | US20080299220A1 | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses | 290 |
| 6 | US20060275218A1 | Foamable vehicle and pharmaceutical compositions thereof | 279 |
| 7 | US20080292560A1 | Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent | 265 |
| 8 | US20080206159A1 | Compositions with modulating agents | 254 |
| 9 | WO2004037225A2 | Cosmetic and pharmaceutical foam | 252 |
| 10 | US20080260655A1 | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses | 245 |
Citation counts accumulate over time and favour older filings; treat them as a signal of influence on later work, not of current commercial weight.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say about the field
Three patterns stand out once concentration, filing pace and classification overlap are read together.
Leadership is concentrated but not locked in
The five leading assignees hold 26.1% of all records in scope, and the top ten reach 36.8%. That leaves well over three-fifths of the field spread across a long tail of entrants with fewer filings each — room for a well-targeted filing to matter.
Volume has passed its peak, not the technology
Filings built steadily to a 2022 peak before easing; the 2021-2024 window shows a 17% pullback. High filing density earlier in the period means claim space in the core AHA-tolerance area is already occupied, but it does not mean the underlying chemistry is exhausted.
Pharmaceutical framing still leads cosmetic framing
A61K medicinal preparations outpaces A61Q cosmetics use (29.2%) by a wide margin, and C07D heterocyclic compounds sits close behind cosmetics use at 27.5%. Filers are still routing tolerance and delivery innovations through pharmaceutical claim language even when the end use is cosmetic.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to exfoliating acids and barrier care, with the prior art for and against each one.
Who is filing, and where the gaps sit
The ranked leaders span pharmaceutical, biotech and consumer-goods filers rather than a single specialist cluster, and recent-year momentum is uneven even among the largest holders.
A single filer sits well ahead of fifth place
The leading assignee holds 190 records against 65 at fifth place and 48 at tenth — a steep drop-off that suggests one large portfolio rather than an even cluster at the top.
Even active filers are pulling back
Recent-year momentum data shows one of the more active assignees filing 7 records in the latest year, down 30% year-on-year, while several other ranked assignees show zero filings in that same latest year. Portfolio activity is not evenly maintained across the leaders.
Co-filing is limited and clustered around one pair
Only ten co-assignee pairings appear in the dataset, and the strongest single pairing far outweighs the others recorded — collaboration in this field is the exception, not the norm.
| Assignee | Recent year | YoY |
|---|---|---|
| Procter & Gamble | 7 | -30% |
| Guangdong Dongyangguang Pharmaceutical Co., Ltd. | 0 | — |
| ImmunoGen, Inc. | 0 | — |
| Lupin Ltd. | 0 | — |
| Liminal BioSciences Ltd. | 0 | — |
| Nimbus Saturn, Inc. | 0 | — |
| Spogen Biotech Inc. | 0 | -100% |
| Il Dong Pharmaceutical Co., Ltd. | 0 | — |
Where to take this analysis
The dataset points to specific follow-up questions rather than a single conclusion.
Check freedom-to-operate against the densest claims
With 71.6% of records carrying an A61K classification, a formulation team should map any new AHA or barrier-lipid composition against that dense cluster before committing to a claim strategy.
Explore claim mapping in EurekaWatch the assignees still filing after the 2022 peak
Overall volume has eased since 2022, but momentum data shows uneven activity among leaders — worth tracking which of the ranked assignees keep filing into 2025-26 once lag clears.
Track assignee momentum in EurekaTest the under-claimed branches for a first-filer position
Smaller IPC shares in A01N, C07K, C12N and C01B suggest adjacent chemistries that have not been heavily claimed against barrier care use cases.
Search white space in EurekaCommon questions on this landscape
The assignee ranking in this dataset shows one filer well ahead of the rest, holding 190 records against 65 at fifth place and 48 at tenth. The five leading assignees together account for 26.1% of all 2,457 records in scope, and the top ten reach 36.8%. Beyond that, the field spreads across a long tail of lower-volume filers, so a competitive check should look past just the top names.
Filing volume rose from 60 records in 2017 to a peak of 228 in 2022, then eased; the 2021-to-2024 window shows a 17% decline from 152 to 126. That said, 2025 and 2026 figures are understated because publication typically lags filing by around 18 months, so it is too early to call this a sustained downturn rather than a plateau after a filing surge.
In this dataset, 71.6% of records carry an A61K medicinal-preparations classification versus 29.2% for A61Q cosmetics use, meaning many tolerance and delivery innovations for exfoliating acids are still claimed through pharmaceutical language even when marketed as cosmetics. The representative filing in this landscape, US20060269495A1, is itself framed as a pharmaceutical composition for treating skin disorders rather than a cosmetic product, which affects how its claims read against a purely cosmetic formulation.
Smaller IPC shares point to under-claimed adjacencies: A01N (biocide-related, 7.4% of records), C07K (peptides and proteins, 5.9%), C12N (microorganisms and genetic engineering, 3.9%) and C01B (inorganic compounds, 3.1%) all sit far below the dominant A61K and A61Q classes. Barrier lipid co-formulation, buffered free-acid-value stabilisation and microbiome-compatible carriers are among the more technically specific gaps worth checking before drafting.
It is moderately concentrated rather than dominated by one player outright. The leading assignee alone holds 190 of 2,457 records, but the top-five combined share is 26.1% and the top-ten share is 36.8%, leaving the majority of records distributed among many smaller filers. Co-filing is also rare: the dataset records only 10 co-assignee pairings, with one pairing far stronger than the rest.
Research Exfoliating Acids and Barrier Care in depth with Eureka
Go past this page: query the whole exfoliating acids and barrier care corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.